Life Sciences Tools & Services
CRL posted modest 1.2% revenue growth to $995.8M in Q1 FY2026, but swung to a net loss of $14.8M despite a 60.6% surge in operating income, as heavy investing outflows and financing activity signal significant strategic repositioning.
Key risk: Deteriorating Free Cash Flow and Liquidity
Operating cash flow collapsed 76.1% year-over-year to just $41.1M from $171.7M, while cash and equivalents declined 16.4% to $191.8M. This sharp deterioration in cash generation, combined with heavy investing outflows of $407.8M, raises near-term liquidity concerns if the trend persists.
Other Life Sciences Tools & Services companies